Development of the novel LDL-receptor targeted liposome formulation for cancer treatment

1 In the proposed work, we planned to develop a novel liposomal paclitaxel formulation in PEGylated liposome conjugated with PCSK9 (PCSK9-PEGLip; PCSK9 conjugated Liposomes). Here we expected to combine the LDL-targeting properties of PCSK9 with the drug delivery properties of sterically stabilized...

Full description

Bibliographic Details
Main Authors: Charbe, Nitin
Other Authors: Pontificia Universidad Catolica De Chile
Format: Report
Language:unknown
Published: 2023
Subjects:
Online Access:https://hdl.handle.net/10533/49139